Allergic bronchopulmonary aspergillosis treated successfully with omalizumab
نویسندگان
چکیده
منابع مشابه
Allergic bronchopulmonary aspergillosis treated successfully with omalizumab.
Allergic bronchopulmonary aspergillosis (ABPA) is caused by a hypersensitivity response of type 2 T helper (Th2) lymphocytes to antigens, mostly Aspergillus fumigatus (A. fumigatus).1 This abnormal host response to A. fumigatus in a subset of patients with asthma or cystic fibrosis (CF) is likely due to genetic susceptibility that predisposes patients to the risk of developing ABPA. This is cha...
متن کاملAllergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab
BACKGROUND Current therapy for allergic bronchopulmonary aspergillosis (ABPA) uses oral corticosteroids, exposing patients to the adverse effects of these agents. There are reports of the steroid-sparing effect of anti-IgE therapy with omalizumab for ABPA in patients with cystic fibrosis (CF), but there is little information on its efficacy against ABPA in patients with bronchial asthma without...
متن کاملAllergic bronchopulmonary aspergillosis and omalizumab.
Allergic bronchopulmonary aspergillosis (ABPA) is most frequently seen in patients suffering from allergic asthma (1). In spite of itraconazole, some patients experience recurrent exacerbations or require long term intensive treatment (steroids) (2). The presence of high levels of IgE, the presence of an often difficult to treat asthma, as well as recent data on the favourable results of the ad...
متن کاملA case of allergic bronchopulmonary aspergillosis successfully treated with mepolizumab
BACKGROUND Allergic bronchopulmonary aspergillosis (ABPA) is an allergic pulmonary disease comprising a complex hypersensitivity reaction to Aspergillus fumigatus. Clinical features of ABPA are wheezing, mucoid impaction, and pulmonary infiltrates. Oral corticosteroids and anti-fungal agents are standard therapy for ABPA, but long-term use of systemic corticosteroids often causes serious side e...
متن کاملAllergic bronchopulmonary aspergillosis treated with itraconazole.
Communications for this section will be published as space and priorities permit. The comments should not exceed 350 words in length, with a maximum of five references; one figure or table can be printed. Exceptions may occur under particular circumstances. Contributions may include comments on articles published in this periodical, or they may be reports of unique educational character. Specif...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Revista Portuguesa de Pneumologia (English Edition)
سال: 2017
ISSN: 2173-5115
DOI: 10.1016/j.rppnen.2017.05.006